Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 35

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 35
---
, as follows: (i) 90% received from the Closing until the 2nd anniversary thereof, (ii) 85% received from the 2nd anniversary of the Closing until the 4th anniversary of the Closing, (iii) 80% received from the 4th 
 anniversary of the Closing until the 6th anniversary of the Closing, and (iv) 75% received from the 6th anniversary of the Closing until the 10th anniversary of the Closing;                                                                    |

| (iii). | 100% of the net proceeds received by the 10th anniversary of the Closing for any license or disposition of the                                                      
 Company’s product candidates and/or intellectual property related to its RP-1664 program, RP-3500 (camonsertib) program, or any other license or disposition of the 
 Company’s product candidates or research programs if such license or disposition is entered into prior to the Closing;                                              |

| (iv). | 100% of the net proceeds received by the 10th anniversary of the Closing for any license or disposition of the 
 Company’s Polq program, RP-3467, to any person with whom negotiations were initiated prior to the Closing;     |

| (v). | 50% of the net proceeds received by the 10th anniversary of the Closing for any license or disposition of the                                                                         
 Company’s product candidates and/or intellectual property that occurs within 10 years following the Closing if such license or disposition is entered into following the Closing; and |

16

| (vi). | 100% of the net proceeds actually received by the 10th                                                                                                                                           
 anniversary of the Closing date on account of certain investment tax credits, tax reimbursements or refunds, to the extent attributable to the period (or portion thereof) prior to the Closing. |

(the “ CVR Consideration,” and together with the cash amount to be paid to Shareholders, the “ Consideration”).

| Q: | What will holders of Options and RSUs receive in the Arrangement? |

| A: | Each Option and RSU outstanding as of the Effective Time (whether vested or unvested) will be deemed to be                                                                                                                                           
 unconditionally vested and exercisable and, without any further action by or on behalf of the holder, shall be deemed to be assigned and surrendered by such holder to the Company in exchange for, (A) in respect of each Option for which the Cash 
 Amount exceeds the applicable exercise price in respect of such Option